Source comparison
MK-677 Comparative Studies: Protocol Comparison
Dosing Frequency Once daily oral Once daily subcutaneous 2–3× daily subcutaneous MK-677 eliminates multiple daily administrations that introduce adherence variability Dose Range Studied 10–50mg (most common: 25mg) 0.3–1.2 IU/kg/week 1–3 mcg/kg per dose MK-677
This comparison does not assign a generated winner or score.
- Dosing Frequency
- Once daily oral
- Once daily subcutaneous
- 2–3× daily subcutaneous
- MK-677 eliminates multiple daily administrations that introduce adherence variability
- Dose Range Studied
- 10–50mg (most common: 25mg)
- 0.3–1.2 IU/kg/week
- 1–3 mcg/kg per dose
- MK-677 dosing is weight-independent in most published trials
- IGF-1 Elevation Pattern
- Sustained 24-hour elevation
- Peak 4–8 hours post-dose
- Pulsatile peaks 30–90 min post-injection
- Sustained vs pulsatile kinetics impact sampling timing and interpretation
- Endogenous GH Suppression
- None documented
- Documented in 70–85% of long-term users
- Minimal to none
- Critical distinction for post-study recovery and long-term safety
- Regulatory Classification
- Research compound (unscheduled in most jurisdictions)
- Schedule III controlled substance
- Varies by compound and jurisdiction
- Impacts procurement, institutional oversight, and reporting requirements
- Professional Assessment
- MK-677's oral bioavailability and lack of endogenous suppression make it methodologically preferable for long-term comparative trials where participant adherence and post-study recovery are endpoints. RhGH remains the gold standard for acute GH elevation studies requiring maximal peak response